Claims
- 1. A method of inducing an immune response that includes a CD8+ cytotoxic T lymphocyte (CTL) response to a molecule in an individual, the method comprising administering to the individual the molecule joined to a heat shock protein or the molecule joined to an adenosinetriphosphate (ATP) binding domain of a heat shock protein or a portion thereof.
- 2. The method of claim 1, wherein the individual has a deficiency of CD4+ T cells.
- 3. The method of claim 1, wherein the heat shock protein is fused to the molecule.
- 4. The method of claim 1, wherein the ATP binding domain is fused to the molecule.
- 5. The method of claim 1, wherein the heat shock protein is covalently bonded or chemically conjugated to the molecule.
- 6. The method of claim 1, wherein the ATP binding domain, or the portion thereof, is covalently bonded or chemically conjugated to the molecule.
- 7. The method of claim 1, wherein the molecule is a protein or glycoprotein.
- 8. The method of claim 1, wherein the molecule is a carbohydrate or lipid.
- 9. The method of claim 1, wherein the molecule is a bacterial or viral antigen.
- 10. The method of claim 10, wherein the viral antigen is an antigen of the human immunodeficiency virus.
- 11. The method of claim 1, wherein the molecule is a parasitic antigen.
- 12. The method of claim 1, wherein the molecule is a cancer cell-associated antigen.
- 13. The method of claim 1, wherein the heat shock protein, the ATP binding domain of the heat shock protein, or the portion thereof, is a mycobacterial protein.
- 14. The method of claim 13, wherein the mycobacterial protein is an M. leprae, M. bovis, or M. tuberculosis protein.
- 15. The method of claim 1, wherein the heat shock protein, the ATP binding domain of the heat shock protein, or the portion thereof, is hsp70, or hsp90.
- 16. The method of claim 1, wherein the heat shock protein, the ATP binding domain of the heat shock protein, or the portion thereof, is a mammalian protein.
- 17. The method of claim 16, wherein the mammalian protein is a human protein.
- 18. The method of claim 1, wherein the portion of the ATP binding domain consists of about half of the ATP binding domain.
- 19. The method of claim 1, wherein the portion of the ATP binding domain is a portion of a naturally occurring ATP binding domain in which 1-50% of the amino acid residues have been substituted; 10-40% of the amino acid residues have been substituted; or 10-20% of the amino acid residues have been substituted.
- 20. The method of claim 19, wherein at least half of the substituted amino acid residues are conservative amino acid substitutions.
- 21. The method of claim 1, wherein the portion of the ATP binding domain comprises amino acid residues 161-370 of Mycobacterium tuberculosis hsp70.
- 22. The method of claim 2, wherein the individual has an acquired immune deficiency syndrome.
- 23. A method of inducing a CD4+ -independent cytotoxic T lymphocyte response to a molecule in an individual, the method comprising administering to the individual a portion of an ATP binding domain of a heat shock protein joined to the molecule.
- 24. The method of claim 23, wherein the molecule is a protein, a peptide, a glycoprotein, a carbohydrate, a viral antigen, a fungal antigen, or a parasitic antigen.
- 25. The method of claim 23, wherein the heat shock protein is an hsp65, hsp70, hsp90, bacterial, mycobacterial, fungal, parasitic, or mammalian heat shock protein.
- 26. A composition comprising a heat shock protein, or a portion thereof, joined to a heterologous molecule.
- 27. The composition of claim 26, wherein the portion of the heat shock protein is a portion of an ATP binding domain of a heat shock protein.
- 28. The composition of claim 26, wherein the heat shock protein, or the portion thereof, is fused to the heterologous molecule.
- 29. The composition of claim 26, wherein the molecule is a protein, peptide, glycoprotein, carbohydrate, viral antigen, fungal antigen, or parasitic antigen.
- 30. The composition of claim 26, wherein the heat shock protein is a mycobacterial or mammalian heat shock protein.
- 31. The composition of claim 30, wherein the mycobacterial heat shock protein is derived from Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium bovis.
- 32. The composition of claim 27, wherein the portion of the ATP binding domain consists of about half of the ATP binding domain.
- 33. The composition of claim 26, wherein the portion of the ATP binding domain is a portion of a naturally occurring ATP binding domain in which 1-50% of the amino acid residues have been substituted; 10-40% of the amino acid residues have been substituted; or 10-20% of the amino acid residues have been substituted.
- 34. The composition of claim 33, wherein at least half of the substituted amino acid residues are conservative amino acid substitutions.
- 35. The composition of claim 26, wherein the portion of the ATP binding domain comprises amino acid residues 161-370 of Mycobacterium tuberculosis hsp70.
GOVERNMENT SUPPORT
[0001] The invention was supported, in part, by National Institutes of Health (NIH) training grant 5T32-AI-07463, NIH Cancer Center core grant CA-14051 and NIH research grants AI44476 and AI44478. The Government has certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60176143 |
Jan 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/32831 |
Dec 2000 |
US |
Child |
09761534 |
Jan 2001 |
US |